Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7228-7238

  Hettiaratchi, Marian H ^a   Miller, Tobias ^a   Temenoff, Johnna S ^a,b   Guldberg, Robert E ^b,c   McDevitt, Todd C ^a,b  

^a Emory University   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alkaline phosphatase; Bone morphogenetic protein; Bone tissue engineering; Glycosaminoglycan; Heparin; Microparticle

Indexed keywords

AUTOMOBILE MANUFACTURE; BIOLOGICAL MATERIALS; BIOMATERIALS; CELL ENGINEERING; ENDOTHELIAL CELLS; PHOSPHATASES; POLYSACCHARIDES; PROTEINS; TISSUE ENGINEERING;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEINS; BONE TISSUE ENGINEERING; GLYCOSAMINOGLYCANS; HEPARIN; MICRO PARTICLES;

BIOACTIVITY;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; DRUG CARRIER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HEPARIN DERIVATIVE; HEPARIN METHACRYLAMIDE MICROPARTICLE; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ACRYLAMIDE DERIVATIVE; BIOMATERIAL; BMP2 PROTEIN, MOUSE; FGFR2 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HEPARIN; METHACRYLAMIDE; NANOPARTICLE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ARTICLE; BIOLOGICAL ACTIVITY; CELL COUNT; CONTROLLED STUDY; DNA CONTENT; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; MUSCLE DEVELOPMENT; MYOBLAST; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STATIC ELECTRICITY; SUSTAINED DRUG RELEASE; TEMPERATURE; ANIMAL; CELL CULTURE; CHEMISTRY; METABOLISM; MOUSE; PROCEDURES; TISSUE ENGINEERING;

ACRYLAMIDES; ALKALINE PHOSPHATASE; ANIMALS; BIOCOMPATIBLE MATERIALS; BONE MORPHOGENETIC PROTEIN 2; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; HEPARIN; MICE; NANOPARTICLES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TISSUE ENGINEERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902118252     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.011     Document Type: Article

References (69)

1. Vaibhav B., Nilesh P., Vikram S., Anshul C. Bone morphogenic protein and its application in trauma cases: a current concept update. Injury 2007, 38:1227-1235.
2. Cahill K.S., Chi J.H., Day A., Claus E.B. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009, 302:58-66.
3. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007, 77:626-631.
4. Ennett A.B., Kaigler D., Mooney D.J. Temporally regulated delivery of VEGF invitro and invivo. JBiomed Mater Res A 2006, 79:176-184.
5. van de Wetering P., Metters A.T., Schoenmakers R.G., Hubbell J.A. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. JControl Release 2005, 102:619-627.
6. Uludag H., D'Augusta D., Palmer R., Timony G., Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. JBiomed Mater Res 1999, 46:193-202.
7. Tao L., Liu J., Xu J., Davis T.P. Synthesis and bioactivity of poly(HPMA)-lysozyme conjugates: the use of novel thiazolidine-2-thione coupling chemistry. Org Biomol Chem 2009, 7:3481-3485.
8. Al-Azzam W., Pastrana E.A., King B., Méndez J., Griebenow K. Effect of the covalent modification of horseradish peroxidase with poly (ethylene glycol) on the activity and stability upon encapsulation in polyester microspheres. JPharm Sci 2005, 94:1808-1819.
9. Lindahl U., Hook M. Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem 1978, 47:385-417.
10. Miller T., Goude M.C., McDevitt T.C., Temenoff J.S. Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery. Acta Biomater 2014, 10:1705-1719.
11. Capila I., Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed Engl 2002, 41:390-412.
12. Schönherr E., Hausser H.-J. Extracellular matrix and cytokines: a functional unit. Dev Immunol 2000, 7:89-101.
13. Deepa S.S., Umehara Y., Higashiyama S., Itoh N., Sugahara K. Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors: implications as a physiological binding partner in the brain and other tissues. JBiol Chem 2002, 277:43707-43716.
14. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996, 237:295-302.
15. Gandhi N.S., Mancera R.L. Prediction of heparin binding sites in bone morphogenetic proteins (BMPs). Biochim Biophys Acta 2012, 1842:1374-1381.
16. Guimond S.E., Turnbull J.E. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr Biol 1999, 9:1343-1346.
17. Slack J., Darlington B., Heath J., Godsave S. Mesoderm induction in early xenopus embryos by heparin-binding growth factors. Nature 1987, 326:197-200.
18. Damon D.H., Lobb R.R., D'Amore P.A., Wagner J.A. Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half-life. JCell Physiol 1989, 138:221-226.
19. Ye L., Wu X., Mu Q., Chen B., Duan Y., Geng X., et al. Heparin-conjugated PCL scaffolds fabricated by electrospinning and loaded with fibroblast growth factor 2. JBiomater Sci Polym Ed 2011, 22:389-406.
20. Liu L.S., Ng C.K., Thompson A.Y., Poser J.W., Spiro R.C. Hyaluronate-heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF-2). JBiomed Mater Res 2002, 62:128-135.
21. Pike D.B., Cai S., Pomraning K.R., Firpo M.A., Fisher R.J., Shu X.Z., et al. Heparin-regulated release of growth factors invitro and angiogenic response invivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 2006, 27:5242-5251.
22. Schroeder-Tefft J., Bentz H., Estridge T. Collagen and heparin matrices for growth factor delivery. JControl Release 1997, 49:291-298.
23. Zhao J., Luo C., Chen Y., Wu D., Shen C., Han W., et al. Preparation, structure and BMP-2 controlled release of heparin-conjugated hyaluronan microgels. Carbohyd Polym 2011, 86:806-811.
24. Xu X., Jha A.K., Duncan R.L., Jia X. Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2. Acta Biomater 2011, 7:3050-3059.
25. Zhao B., Katagiri T., Toyoda H., Takada T., Yanai T., Fukuda T., et al. Heparin potentiates the invivo ectopic bone formation induced by bone morphogenetic protein-2. JBiol Chem 2006, 281:23246-23253.
26. Kanzaki S., Ariyoshi W., Takahashi T., Okinaga T., Kaneuji T., Mitsugi S., et al. Dual effects of heparin on BMP-2-induced osteogenic activity in MC3T3-E1 cells. Pharmacol Rep 2011, 63:1222-1230.
27. Kanzaki S., Takahashi T., Kanno T., Ariyoshi W., Shinmyouzu K., Tujisawa T., et al. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. JCell Physiol 2008, 216:844-850.
28. Hausser H.J., Brenner R.E. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells invitro. JCell Biochem 2004, 91:1062-1073.
29. Yang L., Butcher M., Simon R.R., Osip S.L., Shaughnessy S.G. The effect of heparin on osteoblast differentiation and activity in primary cultures of bovine aortic smooth muscle cells. Atherosclerosis 2005, 179:79-86.
30. Jiao X., Billings P.C., O'Connell M.P., Kaplan F.S., Shore E.M., Glaser D.L. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. JBiol Chem 2007, 282:1080-1086.
31. Takada T., Katagiri T., Ifuku M., Morimura N., Kobayashi M., Hasegawa K., et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. JBiol Chem 2003, 278:43229-43235.
32. Bhakta G., Rai B., Lim Z.X., Hui J.H., Stein G.S., van Wijnen A.J., et al. Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2. Biomaterials 2012, 33:6113-6122.
33. Jeon O., Song S.J., Kang S.-W., Putnam A.J., Kim B.-S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly (l-lactic-co-glycolic acid) scaffold. Biomaterials 2007, 28:2763-2771.
34. Yang H.S., La W.-G., Bhang S.H., Jeon J.-Y., Lee J.H., Kim B.-S. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 2010, 16:1225-1233.
35. Kang S.-W., La W.-G., Kang J.M., Park J.-H., Kim B.-S. Bone morphogenetic protein-2 enhances bone regeneration mediated by transplantation of osteogenically undifferentiated bone marrow-derived mesenchymal stem cells. Biotechnol Lett 2008, 30:1163-1168.
36. Teixeira S., Yang L., Dijkstra P., Ferraz M., Monteiro F. Heparinized hydroxyapatite/collagen three-dimensional scaffolds for tissue engineering. JMater Sci Mater Med 2010, 21:2385-2392.
37. Bramono D.S., Murali S., Rai B., Ling L., Poh W.T., Lim Z.X., et al. Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2). Bone 2012, 50:954-964.
38. Ratanavaraporn J., Tabata Y. Enhanced osteogenic activity of bone morphogenetic protein-2 by 2-O-desulfated heparin. Acta Biomater 2012, 8:173-182.
39. Johnson M.R., Boerckel J.D., Dupont K.M., Guldberg R.E. Functional restoration of critically sized segmental defects with bone morphogenetic protein-2 and heparin treatment. Clin Orthop Relat Res 2011, 469:3111-3117.
40. Cui C., Schwendeman S.P. One-step surface modification of poly (lactide-co-glycolide) microparticles with heparin. Pharm Res 2007, 24:2381-2393.
41. Denizli A. Heparin-immobilized poly(2-hydroxyethylmethacrylate)-based microspheres. JAppl Polym Sci 1999, 74:655-662.
42. Abbah S.A., Liu J., Goh J.C.H., Wong H.-K. Enhanced control of invivo bone formation with surface functionalized alginate microbeads incorporating heparin and human bone morphogenetic protein-2. Tissue Eng Part A 2012, 19:350-359.
43. Hannink G., Geutjes P.J., Daamen W.F., Buma P. Evaluation of collagen/heparin coated TCP/HA granules for long-term delivery of BMP-2. JMater Sci Mater Med 2013, 24:325-332.
44. Seto S.P., Casas M.E., Temenoff J.S. Differentiation of mesenchymal stem cells in heparin-containing hydrogels via coculture with osteoblasts. Cell Tissue Res 2012, 347:589-601.
45. Park Y.D., Tirelli N., Hubbell J.A. Photopolymerized hyaluronic acid-based hydrogels and interpenetrating networks. Biomaterials 2003, 24:893-900.
46. Lim J.J., Hammoudi T.M., Bratt-Leal A.M., Hamilton S.K., Kepple K.L., Bloodworth N.C., et al. Development of nano-and microscale chondroitin sulfate particles for controlled growth factor delivery. Acta Biomater 2011, 7:986-995.
47. Lamprecht M.R., Sabatini D.M., Carpenter A.E. CellProfiler: free, versatile software for automated biological image analysis. Biotechniques 2007, 42:71-75.
48. Ferrara N., Houck K.A., Jakeman L.B., Winer J., Leung D.W. The vascular endothelial growth factor family of polypeptides. JCell Biochem 1991, 47:211-218.
49. Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987, 8:95-114.
50. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., et al. Human tumor necrosis factor. Production, purification, and characterization. JBiol Chem 1985, 260:2345-2354.
51. Uludag H., D'Augusta D., Golden J., Li J., Timony G., Riedel R., et al. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. JBiomed Mater Res 2000, 50:227-238.
52. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. JCell Biol 1994, 127:1755-1766.
53. Jeon O., Powell C., Solorio L.D., Krebs M.D., Alsberg E. Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels. JControl Release 2011, 154:258-266.
54. Jha A.K., Yang W., Kirn-Safran C.B., Farach-Carson M.C., Jia X. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 2009, 30:6964-6975.
55. La W.G., Kwon S.H., Lee T.J., Yang H.S., Park J., Kim B.S. The effect of the delivery carrier on the quality of bone formed via bone morphogenetic protein-2. Artif Organs 2012, 36:642-647.
56. Yamamoto M., Ikada Y., Tabata Y. Controlled release of growth factors based on biodegradation of gelatin hydrogel. JBiomater Sci Polym Ed 2001, 12:77-88.
57. Kawai K., Suzuki S., Tabata Y., Ikada Y., Nishimura Y. Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis. Biomaterials 2000, 21:489-499.
58. Zhao Y., Liu Z., Pan C., Li Z., Zhou J., Wang J., et al. Preparation of gelatin microspheres encapsulated with bFGF for therapeutic angiogenesis in a canine ischemic hind limb. JBiomater Sci Polym Ed 2011, 22:665-682.
59. Mathews S., Mathew S.A., Gupta P.K., Bhonde R., Totey S. Glycosaminoglycans enhance osteoblast differentiation of bone marrow derived human mesenchymal stem cells. JTissue Eng Regen Med 2014, 8:143-152.
60. Kuo W.-J., Digman M.A., Lander A.D. Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization. Mol Biol Cell 2010, 21:4028-4041.
61. Terada K., Misao S., Katase N., Nishimatsu S., Nohno T. Interaction of Wnt signaling with BMP/Smad signaling during the transition from cell proliferation to myogenic differentiation in mouse myoblast-derived cells. Int J Cell Biol 2013, 2013:616294.
62. Ito Y., Shu Qin L., Imanishi Y. Enhancement of cell growth on growth factor-immobilized polymer film. Biomaterials 1991, 12:449-453.
63. Mann B.K., Schmedlen R.H., West J.L. Tethered-TGF-β increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 2001, 22:439-444.
64. Hudalla G.A., Kouris N.A., Koepsel J.T., Ogle B.M., Murphy W.L. Harnessing endogenous growth factor activity modulates stem cell behavior. Integr Biol (Camb) 2011, 3:832-842.
65. Schultz G.S., Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009, 17:153-162.
66. Dombrowski C., Song S.J., Chuan P., Lim X., Susanto E., Sawyer A.A., et al. Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells. Stem Cells Dev 2009, 18:661-670.
67. Furue M.K., Na J., Jackson J.P., Okamoto T., Jones M., Baker D., et al. Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc Natl Acad Sci U S A 2008, 105:13409-13414.
68. Boergermann J.H., Kopf J., Yu P.B., Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol 2010, 42:1802-1807.
69. Gallea S., Lallemand F., Atfi A., Rawadi G., Ramez V., Spinella-Jaegle S., et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001, 28:491-498.